Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy.
Belgium
JC virus
atezolizumab
immune reconstitution inflammatory syndrome
immunotherapy
progressive multifocal leukoencephalopathy
viruses
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
pubmed:
3
12
2021
medline:
7
1
2022
entrez:
2
12
2021
Statut:
ppublish
Résumé
Atezolizumab successfully reinvigorated JC virus immunity in a patient in Belgium with progressive multifocal leukoencephalopathy, as demonstrated by clinical, virologic, and radiologic response to treatment. However, the treatment also resulted in immune reconstitution inflammatory syndrome and life-threatening immune-related adverse events. These conditions were treated with corticosteroids, leading to treatment resistance.
Identifiants
pubmed: 34856110
doi: 10.3201/eid2801.204809
pmc: PMC8714204
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
atezolizumab
52CMI0WC3Y
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Curr Opin Virol. 2020 Feb;40:19-27
pubmed: 32279025
Open Forum Infect Dis. 2019 Sep 30;6(10):ofz374
pubmed: 31660340
Nat Rev Neurol. 2021 Jan;17(1):37-51
pubmed: 33219338
J Exp Med. 2019 Dec 2;216(12):2701-2713
pubmed: 31537643
Mucosal Immunol. 2010 Jan;3(1):81-91
pubmed: 19741598
J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):244-8
pubmed: 22549384
Neurology. 2012 Dec 4;79(23):2258-64
pubmed: 23175722
Emerg Infect Dis. 2019 Nov;25(11):2145-2147
pubmed: 31625858
Neurology. 2013 Apr 9;80(15):1430-8
pubmed: 23568998
Drug Resist Updat. 2019 Jul;45:13-29
pubmed: 31382144